- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00872404
A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma
A Phase II Study of CP-751,871 in Patients With Recurrent and/or Metastatic Squamous Head and Neck Carcinoma
Studieöversikt
Detaljerad beskrivning
CP-751,871 will be administered as an open-label intravenous solution. All patients will be treated every 3 weeks until disease progression(by RECIST criteria) or unacceptable toxicity death or discontinuation from the study for any other reason.
Since, head and neck tumors are easily accessible for iterative biopsy, this study will offer the opportunity to get tumor biopsies before and after CP-751,871. Our study will allow translational research with biopsies at crucial timing:
(i) at baseline before any treatment, (ii) during the treatment with CP-751,871 (day 1, second cycle two hours after the injection of CP-751,871).
(iii) for patients with stable disease or partial response, a new biopsy will be performed at the time of disease progression to try to understand the mechanisms of tumor resistance.
The baseline samples will allow an investigation of molecular profiles that reflect an inherent inter-patient variability and which will be predictive of response. Although the number of patients included is low, these data may contribute to understand the mechanisms of response and non-response to CP-751,871. Understanding the mechanisms of response to CP-751,871 will help in the rational design of further clinical trials in head and neck cancer using CP-751,871.
The on-treatment samples will help to dynamically monitor the molecular response to CP-751,871.
The study of involved pathways before and after administration of CP-751,871 could be performed using IHC, DNA sequence analysis and RNA expression profiling. Plasma samples could be also stored for further analysis.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Bruxelles, Belgien, 1200
- Cliniques Universitaires Saint-Luc
-
-
Namur
-
Yvoir, Namur, Belgien, 5530
- Cliniques Universitaires Mont-Godinne
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Recurrent and/or metastatic head and neck squamous cell carcinoma not amenable to curative treatment with surgery and/or chemotherapy and/or radiation.
- Recurrence must be confirmed by anatomopathology (cytology or biopsy)
- At least one measurable lesion by MRI or CT-scan.
- Failed or relapsing after first line chemotherapy including a platinum* or a taxane-based chemotherapy regimen
- Patients ineligible for chemotherapy could be included in first line
- ECOG performance status 0 -2, in stable medical condition
- Patients must have an expected survival of at least 3 months.
- Paraffin-embedded tumor tissue available for immunohistochemistry
- Patients must be over 18 years old and must be able to give written informed consent
- Women of child-bearing age or sexually active female patients with reproductive potential must have a negative pregnancy test (serum or urine within the 7 days prior to enrollment).
- Patients must have adequate organ function (Hemoglobin ≥ 8 g/100 ml, Neutrophils ≥ 1,000/mm3, Platelets ≥ 75,000/mm3, total bilirubin <1.5 times the upper limit of normal (ULN) for age (except for Gilbert's syndrome patients), serum alanine aminotransferase (ALT) <2.5 ´ ULN for age, aspartate aminotransferase (AST) <2.5 ´ ULN for age , serum creatinine £1.5 x ULN for age
- Acceptance of giving 20 ml of blood for eventual research at baseline
- Acceptance of giving two plasma samples (3ml) at baseline and after 3 weeks of treatment
- Signed informed consent prior to beginning protocol specific procedure
- Sexually active patients must use effective contraception during the period of therapy and up to 150 days after the last dose of CP-751,871. Acceptable contraception includes, but is not limited to: oral hormone therapy, partner vasectomy, or double barrier contraception (which is defined as a male condom plus spermicide in combination with either a female condom, or diaphragm, or cervical cap or intrauterine device).
Exclusion Criteria:
- Non-squamous head and neck cancer
- Nasopharynx cancer
- Brain metastases
- More than two lines of chemotherapy for palliative treatment (except if chemotherapy was given as a part of a multimodal treatment given with a curative intent)
- Surgery or irradiation or investigational drugs within 4 weeks before study inclusion
- Significant active cardiac disease including: uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, or serious cardiac arrhythmias
- Subjects who are receiving chronic high dose immunosuppressive steroid therapy within 2 weeks prior to enrollment (³100 mg prednisone per day or >40 mg dexamethasone per day).
- Other uncontrolled illnesses (active infections requiring antibiotics, bleeding disorders, uncontrolled diabetes …)
- Previous malignancy, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
- Other concomitant anticancer therapies.
- Previous treatment with anti-EGFR therapy is not an exclusion criteria.
- Prior anti-IGF-1R therapy
- Organic brain syndrome or significant psychiatric abnormality that would preclude participation in the full protocol and follow up.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 1
CP-751,871 will be administered as an open-label intravenous solution.
Patients will remain under clinical observation for one hour post-infusion
|
20mg/kg/3 weeks
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Determine the efficacy of CP-751,871 alone in patients with head and neck cancer in term of overall response rate and stable disease (RECIST)
Tidsram: 8 weeks
|
8 weeks
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
To Determine the safety profile of CP-751,871 alone in patients with head and neck cancer. To Determine the efficacy of CP-751,871 alone in patients with head and neck cancer: progression-free survival and survival
Tidsram: 8 weeks
|
8 weeks
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Jean-Pascal Machiels, MDPhD, Cliniques Universitaires Saint-Luc-UCL
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- GORTEC 2008/02
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på CP-751,871
-
PfizerAvslutadSarkom, EwingsFörenta staterna, Storbritannien
-
PfizerAvslutadEwings sarkomfamilj av tumörerSpanien, Frankrike, Förenta staterna, Italien, Australien, Tyskland, Storbritannien, Israel, Kanada, Brasilien, Chile
-
PfizerAvslutad
-
PfizerAvslutadSarkom | Bröstneoplasmer | Lungneoplasmer | Prostatiska neoplasmer | Kolorektala neoplasmerFörenta staterna, Finland, Kanada, Tyskland
-
PfizerAvslutadAvancerade icke-hematologiska maligniteterStorbritannien
-
Suzanne George, MDNovartis; Pfizer; Brigham and Women's HospitalAvslutadRAD001 i kombination med CP-751 871 hos patienter med avancerade sarkom och andra maligna neoplasmerSarkom | Fast tumörFörenta staterna
-
PfizerAvslutadAvancerade solida tumörer | Avancerad cancerFörenta staterna
-
PfizerAvslutadFriska volontärerFörenta staterna
-
PfizerIndragen
-
PfizerAvslutadBröstneoplasmerFörenta staterna, Kanada, Nederländerna, Brasilien, Belgien, Storbritannien, Argentina, Italien, Sverige